Life Sciences Group
RSS Feeds Peertechz

Open Journal of Cell and Protein Science  Open Access


    Response to first-line erlotinib in a false EGFR mutation-negative patient with non-small-cell lung cancer: Make no assumptions e-certificate

    DOI Logo 10.17352/ojcps.000001

    Published On: October 01, 2018 | Pages: 001 - 005

    Author(s): Caixia Deng, Hu Luo and Xiangdong Zhou*
    So far, in the advanced non-small cell lung cancer (NSCLC) with clear epidermal growth factor receptor (EGFR) gene status, the treatment remmendations has reached an agreement: for patients with EGFR mutation-positive, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is the first choice, which can maximize the benefit from the treatment; while f ...
    Abstract View Full Article View Get Citation



    Find more...

    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on OJCPS